65th United States Congress

EQS-News: MorphoSys To Showcase Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2023 ASH Annual Meeting

Retrieved on: 
Tuesday, November 7, 2023
Standard of care, Primary myelofibrosis, Progression-free survival, 65th United States Congress, Ruxolitinib, Research, JAK, Society, Abstract (summary), ASH, Clinical trial, Abstract, FSE, Tafasitamab, BET, Exposition, Patient, TSS, Joint Planning and Development Office, Pharmaceutical industry, Book, MorphoSys

The conference is being held in San Diego, California, from December 9 to 12, 2023.

Key Points: 
  • The conference is being held in San Diego, California, from December 9 to 12, 2023.
  • “We will be sharing topline results from our pivotal MANIFEST-2 study in the coming weeks and look forward to presenting detailed findings at ASH 2023 shortly thereafter.
  • A total of 431 patients were randomized in the study, making it one of the largest myelofibrosis studies conducted to date.
  • One additional abstract on pelabresib and six abstracts on tafasitamab, marketed in the U.S. as Monjuvi® and outside the U.S. by Incyte as Minjuvi®, were accepted for presentation and publication at ASH 2023.

Dizal Highlights Its Advances in Hematological Portfolio at 2023 ASH, Featuring Breakthroughs in Lymphoma Treatment

Retrieved on: 
Friday, November 3, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Janus, DLBCL, Trial of the century, JAK1, Progression-free survival, DOR, CSF, Human, PTCL, 65th United States Congress, PFS, B-cell lymphoma, LYN, Society, ASH, Hematology, Traffic barrier, BBB, Janus kinase 1, Relapse, Peripheral, ORR, NDA, BTK, Patient, Prognosis, ASCO, TAI, Pharmaceutical industry, Vaccine

Golidocitinib is the first and only Janus kinase 1 (JAK1) selective inhibitor in the NDA stage for the treatment of r/r PTCL.

Key Points: 
  • Golidocitinib is the first and only Janus kinase 1 (JAK1) selective inhibitor in the NDA stage for the treatment of r/r PTCL.
  • Golidocitinib monotherapy demonstrated superior efficacy and safety profile in the full analysis of the JACKPOT8 PARTB study, which was consistent with the preliminary findings presented at 2023 ASCO.
  • The pooled analysis results from these two studies will be presented for the first time at 2023 ASH.
  • Golidocitinib in Treating Refractory or Relapsed Peripheral T- Cell Lymphoma: Full Analysis of the Multinational Pivotal Study Results (JACKPOT8)